Business
Novel insight into metastasis in NSCLC patients
Novel insight into metastasis in NSCLC patients.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n \n \n 28 July 2022\n \n \n \n \n \n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n \n \n \n \n CTCS HARVESTED USING THE PARSORTIX SYSTEM PROVIDE NOVEL INSIGHT INTO METASTASIS IN EARLY-STAGE NON-SMALL CELL LUNG CANCER PATIENTS\n \n \n \n \n \n \n \n \n \n Metabolism-Related Genes are overexpressed in the CTCs of early-stage NSCLC patients harvested using Parsortix and are associated with mesenchymal markers\n \n \n \n \n \n \n \n \n \n Identifying the overexpression of metabolic function markers in CTCs may provide new prospective biomarkers to aid diagnosis\n \n \n \n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company,\n is pleased to announce details of a new separate study from the world-class research team led by Prof. Evi Lianidou at the National and Kapodistrian University of Athens, Greece. The study used the Parsortix® system to harvest CTCs from whole blood samples from 46 early-stage non-small cell lung cancer (NSCLC) patients, to analyse the expression of Metabolism-Related Genes (MRGs). Use of the biomarker-independent Parsortix system also allowed the researchers to investigate the association of MRG expression with epithelial and epithelial to mesenchymal transition (EMT) markers.\n \n \n \n \n \n Using the Parsortix system, followed by quantitative PCR (RT-qPCR) analysis, the authors examined the molecular expression of three MRGs in CTCs from early-stage NSCLC patients prior to surgery (baseline), one month following surgery and at relapse. Overexpression of at least one of the three MRGs was detected in 47.8% patients prior to surgery. Analysis of CTCs in patients one month after surgery showed a reduction in the expression of two of the MRGs compared to baseline levels. Subsequently, expression of two of the three MRGs analysed increased in CTCs at relapse.\n \n \n \n \n \n The researchers also demonstrated that overexpression of two MRGs were associated with the overexpression of mesenchymal markers in a subpopulation of CTCs from these early-stage NSCLC patients. The EMT of CTCs is a hallmark of NSCLC and has limited the ability to accurately identify and enumerate CTCs using EpCAM dependent approaches. The use of the biomarker-independent Parsortix syst...